Zometa (Zoledronic Acid) – HCM | HongKong DengYue Medicine

Zometa Zoledronic Acid Application Scope

Zometa is indicated for:

• Hypercalcemia of malignancy (tumor-induced high blood calcium).

• Prevention of skeletal-related events in patients with bone metastases from solid tumors.

• Treatment of osteolytic lesions of multiple myeloma in conjunction with antineoplastic therapy.

  

Zometa Zoledronic Acid Characteristics

• Ingredients: Zoledronic acid (as zoledronic acid monohydrate)

• Properties:​ Zoledronic acid is a bisphosphonic acid that inhibits osteoclastic bone resorption. Forms a clear sterile solution for intravenous use.

• Packaging Specification:​ 4mg/5ml x 1vial

• Storage:​ Store under refrigeration (2°C–8°C / 36°F–46°F) if applicable.

• Expiry Date: 24 months

• Executive Standard: ​See the approved package insert.

• Approval Number: Approval details vary by region; please check the specific approval number.

• Date of Revision: See the latest approved package insert.

• Manufacturer: Novartis Pharmaceuticals Corporation

Guidelines for the Use of Zometa

• Dosage and Administration:

  • Recommended Dose: Hypercalcemia of Malignancy: 4 mg IV over ≥15 minutes (single dose); Bone Metastases / Multiple Myeloma: 4 mg IV over ≥15 min every 3–4 weeks, dose reduction recommended in renal impairment.

  • Administration: Given intravenously (IV) over no less than 15 minutes.

  • Missed Dose:​ Zometa is often given periodically; consult your physician or healthcare provider to reschedule as prescribed.

• Adverse Reactions:

  • Common Adverse Reactions: (Commonly reported >10%) include: fever, nausea, fatigue, bone pain, constipation, vomiting, dyspnea (shortness of breath)

  • Serious Adverse Reactions: Renal toxicity、hypocalcemia (may be severe), osteonecrosis of the jaw (ONJ), Severe bone, joint, muscle pain, atypical femoral fractures, hypersensitivity reactions, including rare anaphylaxis.

    ​

• Contraindications: Known hypersensitivity to zoledronic acid or excipients and non-corrected hypocalcemia.

• Precautions:

  • Assess and correct hypocalcemia before treatment.
  • Adequately hydrate patients before administration.
  • Monitor renal function before each dose.
  • Dental examination recommended prior to therapy (due to ONJ risk).
  • Not generally recommended in severe renal impairment.

Zoledronic Acid Interactions

• Aminoglycosides: may increase risk of prolonged low calcium.
• Loop diuretics: increased risk of hypocalcemia.
• Nephrotoxic drugs: additive renal risk.
• May interact with other bisphosphonates; avoid overlap.

 

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.